IMEIK(SZ:300896) KAIYUAN SECURITIES·2025-08-21 07:27Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a decline in net profit attributable to shareholders by 29.6% year-on-year for H1 2025, indicating performance pressure [5] - Revenue for H1 2025 was 1.299 billion yuan, down 21.6% year-on-year, with Q2 2025 revenue at 636 million yuan, a decrease of 25.1% [5] - The company plans to distribute a cash dividend of 12.00 yuan per 10 shares (including tax), with a payout ratio of 45.82% [5] - Despite the competitive market, the company’s R&D pipeline is progressing steadily, and external expansion is expected to drive growth, leading to a reasonable valuation and a maintained "Buy" rating [5] Financial Performance Summary - For H1 2025, the company's solution products generated revenue of 744 million yuan (down 23.8%), with a gross margin of 93.2% [6] - Gel products achieved revenue of 493 million yuan (down 24.0%), with a gross margin of 97.8% [6] - The overall gross margin for H1 2025 was 93.4%, down 1.5 percentage points, and the net margin was 60.9%, down 6.8 percentage points [6] - The company’s sales, management, and R&D expense ratios were 11.1%, 5.3%, and 12.1%, respectively, with year-on-year increases of 2.6, 1.2, and 4.5 percentage points [6] Growth Drivers - The company is enhancing its growth trajectory through the acquisition of REGEN, which is expected to create a second growth curve [7] - The product line includes market-leading offerings and new products like the "Hao Ke La" launched in May 2025 [7] - The company has obtained 12 Class III medical device registrations, with the second-generation implant line nearing registration [7] - The acquisition of REGEN Biotech has expanded the product matrix, with approvals in 35 and 23 countries for its AestheFill and PowerFill products, respectively [7] Financial Projections - Revenue projections for 2025-2027 are 1.7 billion, 2.005 billion, and 2.325 billion yuan, respectively, with corresponding EPS of 5.62, 6.63, and 7.68 yuan [5][8] - The company’s P/E ratios for 2025-2027 are projected to be 33.5, 28.5, and 24.5 times, respectively [8]